GoldenGolden
Advanced Search
Viome

Viome

Viome is a company that offers gut microbiome testing services, founded by Deepak Savadatti and Naveen Jain.

Viome is a health company that has the goal of discovering predictive biomarkers in order to get rid of all diseases. The company was founded by Deepak Savadatti and Naveen Jain in 2016, in Los Alamos, New Mexico, USA.

The company's artificial learning engines analyze and aggregate all biological data the receive, allowing the machine learning to find trends, patterns, and influences, and ultimately breakthroughs. The way the data is collected is through a microbiome analysis kit customers use to get a snapshot of the microbes living inside their gut. Then Viome offers basic recommendations on how dietary changes could affect their health. Assessing microbiome health and maintaining it can reduce or slow progressions of diseases like depression, osteoarthritis, functional bowel diseases, and multiple sclerosis. Viome aims to use user data to spot trends in gut biome health and support scientific research in the area.

Viome has raised over $25 million and pursues about 15 clinical research trials and is focused on eventually developing treatments. Their tests have origins from technology from a company, BlueDot, which is from Los Alamos National Laboratory. They test a variant on sequencing ribonucleic acid, or the messenger mechanism that provides cells with instructions on what to produce.

Viome sequences the users RNA and can identify and quantify all of the living microorganisms in the gut (bacteria, viruses, bacteriophages, archaea, fungi, yeast, parasites, and more) at the species and strain level.

Timeline

August 2017
Viome raises a $15,000,000 series A round from Bold Capital Partners and Khosla Ventures.

Funding rounds

People

Name
Role
LinkedIn

Deepak Savadatti

Co-Founder, President

Helen Messier

CMO

Naveen Jain

Co-Founder, CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Andrea Park
May 7, 2021
FierceBiotech
Viome's saliva test has received the FDA's breakthrough device designation for use in early screening for oral squamous cell carcinoma and oropharyngeal cancer, both of which are typically only diagnosed in a manual examination and are therefore often overlooked until their later stages.
Annalee Armstrong
April 15, 2021
FierceBiotech
GlaxoSmithKline's Emmanuel Hanon will depart as vaccines R&D chief to explore the microbiome at Viome after a year in which the pharmaceutical giant took a restrained approach to COVID-19 R&D.
BioSpace
April 15, 2021
BioSpace
Viome, a mission-driven systems biology company aiming to help individuals improve their health, today announced the appointment of Dr. Emmanuel Hanon as Global Head of Research and Development (R&D)
Andrew Dunn
April 15, 2021
Business Insider
Insider recently revealed an exodus of vaccine talent from GSK in the US, after the company shied away from coronavirus vaccine efforts.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.